Isolation and characterization of CD146+ multipotent mesenchymal stromal cells

Sorrentino, Antonio; Ferracin, Manuela; Castelli, Germana; Biffoni, Mauro; Tomaselli, Giada; Baiocchi, Marta; Fatica, Alessandro; Negrini, Massimo; Peschle, Cesare; Valtieri, Mauro

doi:10.1016/j.exphem.2008.03.004

Cited by 229 publications

(197 citation statements)

References 66 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…The significance of the latter finding is not clear. Neverthemultilineage differentiation capacity) (78). The use of CD146 as a general marker for MSCs has been disputed less, the absence of a direct relation between ALPL and SSEA-4 surface levels and MSC replication rate and/or due to differences in its surface expression between MSCs derived from different donors and/or sources multipotency (compare AT-MSCs to SM-MSCs) raises doubt as to whether these proteins have similar functions (44,61).…”

Section: Mscs From All Three Human Sources Form Hybrid Ber Of Hybrid mentioning

confidence: 99%

Myogenic Properties of Human Mesenchymal Stem Cells Derived from Three Different Sources

et al. 2012

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) of mammals have been isolated from many tissues and are characterized by their aptitude to differentiate into bone, cartilage, and fat. Differentiation into cells of other lineages like skeletal muscle, tendon/ligament, nervous tissue, and epithelium has been attained with MSCs derived from some tissues. Whether such abilities are shared by MSCs of all tissues is unknown. We therefore compared for three human donors the myogenic properties of MSCs from adipose tissue (AT), bone marrow (BM), and synovial membrane (SM). Our data show that human MSCs derived from the three tissues differ in phenotype, proliferation capacity, and differentiation potential. The division rate of AT-derived MSCs (ATMSCs) was distinctly higher than that of MSCs from the other two tissue sources. In addition, clear donorspecific differences in the long-term maintenance of MSC proliferation ability were observed. Although similar in their in vitro fusogenic capacity with murine myoblasts, MSCs of the three sources contributed to a different extent to skeletal muscle regeneration in vivo. Transplanting human AT-, BM-, or SM-MSCs previously transduced with a lentiviral vector encoding β-galactosidase into cardiotoxin-damaged tibialis anterior muscles (TAMs) of immunodeficient mice revealed that at 30 days after treatment the frequency of hybrid myofibers was highest in the TAMs treated with AT-MSCs. Our finding of human-specific β-spectrin and dystrophin in hybrid myofibers containing human nuclei argues for myogenic programming of MSCs in regenerating murine skeletal muscle. For the further development of MSC-based treatments of myopathies, AT-MSCs appear to be the best choice in view of their efficient contribution to myoregeneration, their high ex vivo expansion potential, and because their harvesting is less demanding than that of BM-or SM-MSCs.

show abstract

Section: Mscs From All Three Human Sources Form Hybrid Ber Of Hybrid mentioning

confidence: 99%

Myogenic Properties of Human Mesenchymal Stem Cells Derived from Three Different Sources

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The level of hepatocyte growth factor expression has been shown to be much higher in placenta-derived mesenchymal stem cells, compared to adult mesenchymal stem cells (Zhu et al 2014). Mesenchymal stem cells can produce a large number of interleukin (IL)-6, IL-7, IL-11, stromal cell-derived factor, leukemia inhibitor factor, stem cell factor, and Flt3 ligand, which are several essential hematopoietic growth factors (Grebnev et al 2015;Chaudhary et al 1992;Tolar et al 2010;Zhang et al 2011;Dazzi et al 2006;Yañez et al 2006;Sorrentino et al 2008). IL-6 can activate the immune and hematopoietic systems (Lazzari et al 2001).…”

Section: Discussionmentioning

confidence: 99%

Multiplacenta derived stem cell/cytokine treatment increases survival time in a mouse model with radiation-induced bone marrow damage

Wei

Yan

et al. 2016

Cytotechnology

View full text Add to dashboard Cite

Nuclear Warfare and nuclear leakage can result in a large number of patients with radiationinduced bone marrow damage. Based on the fact that hematopoietic stem cells and hematopoietic growth factors are characterized as a novel strategy for therapy, the aim of this study was to explore a safe and routine stem cell/cytokine therapeutic strategy. Allogeneic multiplacenta derived hematopoietic and mesenchymal stem cells/cytokines were intraperitoneally injected into a moderate dose of total body irradiation-induced mouse bone marrow damage model a single time. Then, the mouse posttransplantation survival time, peripheral blood hemoglobin count, bone marrow architecture, and donor cell engraftment were assessed. Each mouse that received placenta-derived stem cells exhibited positive donor hematopoietic and mesenchymal stem cell engraftment both in the bone marrow and peripheral blood after transplantation. The peripheral blood hemoglobin count and survival time were greater in the group with the combined treatment of multiplacenta-derived stem cells and cytokines, compared with model-only controls (both P \ 0.001). The blood smear mesenchymal/hematopoietic stem cell count was significantly higher in the combined treatment group than in the mice treated only with placenta-derived cells (28.08 ± 5.824 vs. 20.40 ± 5.989, P \ 0.001; 7.74 ± 2.153 vs. 4.23 ± 1.608, P \ 0.001, respectively). However, there was no marked change on the bone marrow pathology of any of the experimental mice after the transplantation. These results indicate that for radiation-induced bone marrow damage treatment,

show abstract

“…The minimal criteria identified by the International Society for Cellular Therapy for identifying MSCs requires the cells: 1) to be plastic adherent while maintained in cell culture; 2) to express CD73, CD90, and CD105, and lack expression of CD11b, CD14, CD19, CD34, CD45, CD79-alpha, and HLA-DR; and 3) to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro (Dominici et al, 2006;Claros et al, 2008;. Additional studies have also suggested that CD146 is considered an important marker of BM progenitor cells (Sorrentino et al, 2008). These guidelines were set in place to enable a unified approach for comparison amongst different studies.…”

Section: Mesenchymal Stem Cells As Candidatesmentioning

confidence: 99%